Edited by Harald Bathelt, Patrick Cohendet, Sebastian Henn and Laurent Simon
Chapter 40: Institutional entrepreneurship in Alzheimer’s disease treatment
The problem of interest in this exploratory study is the emergence of innovative practices for the treatment of Alzheimer’s Disease (AD). Since there is little prior research on what specific activities are needed to introduce and sustain new practices in complex healthcare fields, we compare three cases of non-pharmacological AD treatment practices in Switzerland. In the first case, no radically new practices were introduced and only minimal change was intended. In the second case, a new referral and consultation process was initiated, and the change was symbolically endorsed but not fully implemented in practice and therefore was decoupled from recommendations by policy makers. In the third case, the change initiator targeted divergent change in AD treatment. He developed a new virtual reality game for early diagnosis and delay of AD symptoms, won a social enterprise fellowship and secured financing by business and philanthropic actors, thereby mobilizing new allies in the field of AD treatment. We find that active participation in vision creation, the acquisition of allies, and resource mobilization are crucial to the success of divergent change initiations. Based on the results, some preliminary policy and managerial implications are offered.
You are not authenticated to view the full text of this chapter or article.
Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.
Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.
Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.